Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy

NCT03951012 · clinicaltrials.gov ↗
TERMINATED
Status
29
Enrollment
OTHER
Sponsor class

Stopped low enrollment and remaining oncologist workload

Conditions

Interventions

Sponsor

Muhammad Furqan

Collaborators